Document is current
Any future updates will be listed below
-
Authors
Hvid, Karen https://orcid.org/0009-0006-4889-2679
Balling, Mie https://orcid.org/0000-0003-2829-2298
Afzal, Shoaib https://orcid.org/0000-0002-1442-4694
Nordestgaard, Børge Grønne https://orcid.org/0000-0002-1954-7220
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 14 April 2026
Accepted: 23 August 2026
First Online: 5 September 2026
Declarations
Ethics approval and consent to participate: Both cohorts represent ongoing, prospective general population studies, approved by local institutional review boards, local data protection agencies, and by ethical committees (Copenhagen General Population Study: H-KF-01-144/01; UK Biobank: 11/NW/0382). This research was conducted using the UK Biobank Resource under application number 104807. All participants provided written informed consent prior to participation.
Consent for publication: The data in this manuscript has not previously been presented.
Competing interest: B.G.N. reports consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, and Merck. K.H. reports consultancy for Merck. S.A. reports travel grant from Abbott. M.B. has nothing to declare.
